Treatment with Insulin Secretagogues and Cancer-Related Mortality in Type 2 Diabetic Patients A Retrospective Cohort Study

Abstract

Background: Recent evidence suggests that some hypoglycemic treatments could affect the incidence of malignancies. This study was aimed at the assessment of cancer-related mortality in type 2 diabetic patients treated with different hypoglycemic drugs.

Methods: A retrospective observational cohort study was performed on a consecutive series of 3002 type 2 diabetic outpatients. Cancer-related death was identified through the City Registry Office. For patients visited for the first time after January 1^st, 2000, information on incidence of cancer was also available.

Results: During a mean follow-up of 4.3±2.5 years, 87 cases of cancer-related death were recorded, with a yearly incidence rate of 0.70%. Patients receiving secretagogues showed a significantly higher mortality than the rest of the sample (unadjusted OR [95%CI] 1.76 [1.15-2.69], p=0.009), which was maintained after adjustment for confounders (HR 2.29 [1.21-4.02], p=0.003). Conversely, no significant association of cancer-related mortality was observed with insulin sensitizers or exogenous insulin. In comparison with patients receiving no hypoglycemic treatment, those on secretagogue or insulin monotherapy showed a higher cancer-related mortality (HR 2.25 [1.10-4.78], p=0.034 and HR 2.11 [1.01-4.50], p=0.048, respectively). The effect of treatments on incidence of malignancies was similar to that observed on cancer-related death.

Conclusions Insulin secretagogues and, to a lesser extent, exogenous insulin, appear to be associated with increased mortality for cancer, even after adjustment for multiple confounders. This issue deserves further investigation through epidemiological studies on larger samples of patients.

Key words

diabetes mellitus - hypoglycemic drugs - cancer - glibenclamide

References

• 1 Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.  Am J Epidemiol. 2004;  159 1160-1167
• 2 Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus.  Int J Cancer. 1997;  71 360-363
• 3 Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer.  A meta-analysis. JAMA. 1995;  273 1605-1609
• 4 Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults.  Cancer Causes Control. 1998;  9 403-410
• 5 Stolzenberg-Solomon RZ, Graubard BI, Chari S. et al . Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.  JAMA. 2005;  294 2872-2878
• 6 Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large US Cohort.  Cancer Epidemiol Biomarkers Prev. 2005;  14 459-466
• 7 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients.  BMJ. 2005;  330 1304-1305
• 8 Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.  Diabetes Care. 2006;  29 254-258
• 9 Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.  Gastroenterology. 2004;  127 1044-1050
• 10 Chalmers J, MacMahon S, Mancia G. et al . World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization.  Clin Exp Hypertens. 1999;  21 1009-1060
• 11 Armstrong D, Lavery L, Vela S, Quebedeaux T, Fleischli J. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.  Arch Intern Med. 1998;  158 289-292
• 12 Blackburn H. Classification of the electrocardiogram for population studies: minnesota code.  J Electrocardiol. 1969;  2 305-310
• 13 Charlson M, Szatrowski T, Peterson T, Gold J. Validation of a combined comorbidity index.  J Clin Epidemiol. 1994;  47 1245-1251
• 14 Del Giudice ME, Fantus IG, Ezzat S, Keown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk.  Breast Cancer Res Treat. 1998;  47 111-120
• 15 Yam D, Fink A, Mashiah A, Ben-Hur E. Hyperinsulinemia in colon, stomach and breast cancer patients.  Cancer Lett. 1996;  104 129-132
• 16 Vecchia C La, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk.  Br J Cancer. 1994;  70 950-953
• 17 Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women.  JAMA. 2005;  293 194-202
• 18 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US.  adults. N Engl J Med. 2003;  348 1625-1638
• 19 Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome.  Cancer Epidemiol Biomarkers Prev. 2002;  11 385-391
• 20 Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality.  Cancer Epidemiol Biomarkers Prev. 2001;  10 937-941
• 21 Chiu HM, Lin JT, Shun CT. et al . Association of metabolic syndrome with proximal and synchronous colorectal neoplasm.  Clin Gastroenterol Hepatol. 2006; 
• 22 Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer.  Cancer. 2006;  107 28-36
• 23 Cowey S, Hardy RW. The metabolic syndrome. A high-risk state for cancer?.  Am J Pathol. 2006;  169 1505-1522
• 24 Rosenfeld RG. Insulin-like growth factors and the basis of growth.  N Engl J Med. 2003;  349 2184-2186
• 25 Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Circulation. 2004;  109 433-438
• 26 Kuhl H. Breast cancer risk in the WHI study. The problem of obesity.  Maturitas. 2005;  51 83-97
• 27 Monami M, Luzzi C, Lamanna C. et al . Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.  Diabetes Metab Res Rev. 2006;  22 477-482
• 28 Monami M, Balzi D, Lamanna C. et al . Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.  Diabetes Metab Res Rev. 2007;  , Epub ahead of print

Correspondence